New Zealand markets open in 7 hours 6 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.9786-0.0116 (-1.17%)
As of 09:54AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 105.95M
Enterprise value 230.60M
Trailing P/E N/A
Forward P/E 0.57
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.93
Price/book (mrq)74.89
Enterprise value/revenue 2.62
Enterprise value/EBITDA -1.40

Trading information

Stock price history

Beta (5Y monthly) 0.13
52-week change 3-85.44%
S&P500 52-week change 318.19%
52-week high 38.8700
52-week low 30.8500
50-day moving average 31.4768
200-day moving average 33.0074

Share statistics

Avg vol (3-month) 33.39M
Avg vol (10-day) 35.97M
Shares outstanding 5106.99M
Implied shares outstanding 6106.99M
Float 886.08M
% held by insiders 10.51%
% held by institutions 185.75%
Shares short (30 Aug 2023) 415.18M
Short ratio (30 Aug 2023) 44.04
Short % of float (30 Aug 2023) 417.32%
Short % of shares outstanding (30 Aug 2023) 414.19%
Shares short (prior month 30 Jul 2023) 413.41M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin -252.82%
Operating margin (ttm)-193.14%

Management effectiveness

Return on assets (ttm)-39.41%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)87.91M
Revenue per share (ttm)1.07
Quarterly revenue growth (yoy)36.90%
Gross profit (ttm)-70.42M
EBITDA -169.47M
Net income avi to common (ttm)-222.26M
Diluted EPS (ttm)-2.4000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)138.47M
Total cash per share (mrq)1.29
Total debt (mrq)522.9M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.17
Book value per share (mrq)-3.69

Cash flow statement

Operating cash flow (ttm)-164.41M
Levered free cash flow (ttm)-130.88M